Montreux, Switzerland – April 4, 2023. MedXCell SA, a Swiss biotech venture builder, is pleased to announce that its paper “Novel trehalose-based excipients for stabilizing nebulized anti- SARS-CoV-2 antibody” has been published in the International Journal of Pharmaceutics and is now accessible online here.
This work describes the development of new liquid formulations of biological drugs with the potential for direct delivery via nebulization into the respiratory tract. Favouring innovation, and through an exceptional academic collaboration with the Federal Institute of Technology in Lausanne (EPFL) and academic institutions in Montpellier (CNRS, CHU Montpellier, INSERM, IRMB, ICM), MedXCell worked with researchers to conceptualize, synthesize and test a new family of functional excipient molecules with the potential to protect and enhance the activity of biological drugs (particularly antibody drugs) and thus make liquid formulation and conventional nebulizer delivery feasible.
Using the best candidate functional excipient, MedXCell was able to demonstrate successful delivery of a SARS- CoV-2 neutralizing monoclonal antibody into the entirety of the respiratory tract of experimental mice, with concomitant prophylactic and post-exposure protection from SARS-CoV-2 pathology.
MedXCell is now seeking licensees, partners or acquirers of this technology from companies with interest in delivering active biological drugs for pulmonary diseases directly to the site of action as an alternative to systemic administration (including but not limited to respiratory viruses).
About MedXCell
MedXCell is a Swiss biotech venture builder led by entrepreneurs and backed by private investors. Our operating model is to co-design early-stage projects with academic institutions, followed by the creation of independent business ventures centered around the most commercially-viable ideas. MedXCell subsequently finances and manages the operations of these ventures before integrating co-investors for later-stage development. MedXCell’s current portfolio includes CYTEA BIO and BIORESPX, two robust technological platforms that have advanced to the non-clinical proof of concept (POC) stage.
